Avelumab manufacturers
- Avelumab
-
- $987.00
-
2026-05-21
- CAS:1537032-82-8
- Purity: 95.00%
- Supply Ability: 10g
|
| | Avelumab Basic information |
| Product Name: | Avelumab | | Synonyms: | Avelumab;Avelumab (anti- PD-L1);Avelumab (MSB0010718C);Avelumab (Anti-Human PD-L1, Human Antibody);Research Grade Avelumab(DHJ70103);Research Grade Avelumab;Avelumab - in PBS buffer;MSB0010718C | | CAS: | 1537032-82-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Avelumab Structure]() |
| | Avelumab Chemical Properties |
| storage temp. | Store at 4°C, do not freeze | | solubility | Soluble in DMSO | | form | Liquid | | color | Colorless to light yellow |
| | Avelumab Usage And Synthesis |
| Uses | Avelumab, sold under the brand name Bavencio, is a fully human
monoclonal antibody medication for the treatment of Merkel cell
carcinoma, urothelial carcinoma, and renal cell carcinoma. | | in vivo | Measurement of individual tumors clearly shows a slowing of tumor growth in the Avelumab-treated mice. By day 36 post-tumor implantation, there is a significant (P<0.01) reduction in the average tumor volume of the Avelumab-treated mice. Reduction in MB49 tumor growth in the mice treated with Avelumab is durable and leads to a significant (P<0.05) improvement in percent survival. Avelumab treatment of 10 mice with bladder tumors results in complete tumor regression in 8 mice, confirmed by histopathology. However, in mice depleted of either CD4 or CD8 cells, Avelumab treatment is much less effective in controlling bladder tumor burden with tumor breakthrough occurring in a higher frequency in mice depleted of CD4 T cells[3]. |
| | Avelumab Preparation Products And Raw materials |
|